Download PDF
Z Gastroenterol 2003; 41(1): 54-61
DOI: 10.1055/s-2003-36670
Leitlinien der DGVS
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

Extraintestinale Manifestationen

Extraintestinal ManifestationsG. Adler1 , M. Reinshagen1
  • 1Abt. Innere Medizin I, Medizinische Universitätsklinik Ulm
Further Information

Publication History

Publication Date:
16 January 2003 (online)

Also available at
    Permissions and Reprints

Definition extraintestinaler Manifestationen bei Morbus Crohn

Konsens

Erkrankungen außerhalb des GI-Traktes bei Patienten mit Morbus Crohn, bei denen aufgrund der klinischen Assoziation oder pathogenetischer Mechanismen ein Zusammenhang mit der entzündlichen Darmerkrankung besteht oder vermutet werden muss (B).

Hiervon werden extraintestinale Begleiterkrankungen (Gallensteine, Nierensteine) und nicht krankheitsspezifische Komplikationen (Amyloidose, Osteoporose, thromboembolische Komplikationen) abgegrenzt (B).

Literatur

  • 1 Orchard T R, Wordsworth B P, Jewell D P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.  Gut. 1998;  42 387-391 (III)
    Google Scholar
  • 2 Greenstein A J, Janowitz H D, Sachar D B. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients.  Medicine (Baltimore). 1976;  55 401-412 (III)
    Google Scholar
  • 3 Gran J T, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn’s disease.  Digest Dis. 1992;  10 274-294 (III)
    Google Scholar
  • 4 de Vlam K, Mielants H, Cuvelier C. et al . Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.  J Rheumatol. 2000;  27 2860-2865 (III)
    Google Scholar
  • 5 Protzer U, Duchmann R, Hohler T. et al . Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association.  Med Klin. 1996;  91 330-335 (III)
    Google Scholar
  • 6 Braun J, Bollow M, Remlinger G A. et al . Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.  Arthritis Rheum. 1998;  41 58-67 (III)
    Google Scholar
  • 7 Scott W W Jr, Fishman E K, Kuhlman J E. et al . Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation.  Skeletal Radiol. 1990;  19 207-220 (III)
    Google Scholar
  • 8 Stein H, Volpin G, Shapira D. et al . Musculoskeletal manifestations of Crohn’s disease.  Bull Hosp Jt Dis. 1993;  53 17-20 (III)
    Google Scholar
  • 9 Ferraz M B, Tugwell P, Goldsmith C H. et al . Meta-analysis of sulfasalazine in ankylosing spondylitis.  J Rheumatol. 1990;  17 1482-1486 (Ia)
    Google Scholar
  • 10 Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.  Br Med J (Clin Res Ed). 1986;  293 911-914 (Ib)
    Google Scholar
  • 11 Dougados M, vam d er Linden S, Leirisalo-Repo M. et al . Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.  Arthritis Rheum. 1995;  38 618-627 (Ib)
    Google Scholar
  • 12 Mielants H, Veys E M. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis.  J Rheumatol. 1985;  12 287-293 (III)
    Google Scholar
  • 13 Dougados M, Maetzel A, Mijiyawa M. et al . Evaluation of sulphasalazine in the treatment of spondyloarthropathies.  Ann Rheum Dis. 1992;  51 955-958 (III)
    Google Scholar
  • 14 Thomson G T, Thomson B R, Thomson K S. et al . Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies.  J Rheumatol. 2000;  27 714-718 (III)
    Google Scholar
  • 15 Florin T H, Graffner H, Nilsson L G. et al . Treatment of joint pain in Crohn’s patients with budesonide controlled ileal release.  Clin Exp Pharmacol Physiol. 2000;  27 295-298 (III)
    Google Scholar
  • 16 Brandt J, Haibel H, Cornely D. et al . Successful treatment of active ankylosing spondylitis with the anti- tumor necrosis factor alpha monoclonal antibody infliximab.  Arthritis Rheum. 2000;  43 1346-1352 (III)
    Google Scholar
  • 17 Van den Bosch F, Kruithof E. et al . Crohn’s disease associated with spondyloarthropathy: effect of TNF- alpha blockade with infliximab on articular symptoms.  Lancet. 2000;  356 1821-1822 (III)
    Google Scholar
  • 18 Felder J B, Korelitz B I, Rajapakse R. et al . Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.  Am J Gastroenterol. 2000;  95 1949-1954 (III)
    Google Scholar
  • 19 Evans J M, McMahon A D, Murray F E. et al . Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease.  Gut. 1997;  40 619-622 (III)
    Google Scholar
  • 20 Bonner G F, Walczak M, Kitchen L. et al . Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease.  Am J Gastroenterol. 2000;  95 1946-1948 (III)
    Google Scholar
  • 21 Rasmussen H H, Fallingborg J E, Mortensen P B, Vyberg M, Tage-Jensen U, Rasmussen S N. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn ‘s disease.  Scand J Gastroenterol. 1979;  32 604-610 (III)
    Google Scholar
  • 22 Bernstein C N, Blanchard J F, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study.  Am J Gastroenterol. 2001;  96 1116-1122 (IIb)
    Google Scholar
  • 23 Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B. Primary sclerosing cholangitis in patients with chronic inflammatory bowel disease in Turkey.  J Clin Gastroenterol. 2001;  33 299-301 (III)
    Google Scholar
  • 24 Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann W J, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo controlled study period.  J Hepatol. 1994;  20 57-64 (Ib)
    Google Scholar
  • 25 Stiehl A, Rudolph G, Sauer P. et al . Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis.  J Hepatol. 1997;  26 560-566 (Ib)
    Google Scholar
  • 26 Mitchell S A, Bansi D S, Hunt N, von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907 (Ib)
    Google Scholar
  • 27 Lee J G, Schutz S M, England R E, Leung J W, Cotton P B. Endoscopic therapy of sclerosing cholangitis.  Hepatology. 1995;  21 661-667 (Ib)
    Google Scholar
  • 28 Harnois D M, Angulo P, Jorgensen R A, Larusso N F, Lindor K D. High-dose ursodeoxycholic acid as a therapy für patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1558-1562 (Ib)
    Google Scholar
  • 29 Broomé U, Olsson R, Loof L. et al . Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.  Gut. 1996;  38 610-615 (III)
    Google Scholar
  • 30 Heathcote J. Autoimmune cholangitis and overlap syndromes. In: Diseases of the bile duct: Pathogenesis, pathology and practice.  Postgraduate course of the American Association for Study of the Liver Diseases. 1996;  121-131 (III)
    Google Scholar
  • 31 Gregory B, Ho V C. Cutaneous manifestations of gastrointestinal disorders. Part II.  J Am Acad Dermatol. 1992;  26 371-383 (III)
    Google Scholar
  • 32 Kirsch B, Gerhardt H, Gladisch R. et al . Dermatosen bei chronisch entzündlichen Darmerkrankungen. Ergebnisse einer Untersuchung von 119 M.-Crohn-/C.-ulcerosa-Patienten.  Akt Dermatol. 1992;  18 17-22 (III)
    Google Scholar
  • 33 Blitz N M, Rudikoff D. Pyoderma gangrenosum.  Mount Sinai J Med. 2001;  68 287-297 (III)
    Google Scholar
  • 34 Tromm A, May D, Almus E. et al . Cutaneous manifestations in inflammatory bowel disease.  Z Gastroenterol. 2001;  39 137-144 (III)
    Google Scholar
  • 35 Latkany P A, Jabs D A. Ocular manifestations of inflammatory bowel disease. Bayless TM, Hanauer SB Advanced therapy of inflammatory bowel disease London; B.C. Decker 2001: 275-277 (III)
    Google Scholar
  • 36 Soukiasian S H, Foster C S, Raizman M B. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.  Am J Ophthalmol. 1994;  118 601-611 (IIb)
    Google Scholar
  • 37 Rickli H, Fretz C, Hoffman M. et al . Severe inflammatory upper airway stenosis in ulcerative colitis.  Eur Respir J. 1994;  7 1899-1902 (III)
    Google Scholar
  • 38 Munck A, Murciano D, Pariente R. et al . Latent pulmonary function abnormalities in children with Crohn’s disease.  Eur Respir J. 1995;  8 377-381 (III)
    Google Scholar
  • 39 Camus P, Piard F, Ashcroft T. et al . The lung in inflammatory bowel disease.  Medicine. 1993;  72 151-83 (III)
    Google Scholar
  • 40 Mahadeva R, Walsh G, Flower C D. et al . Clinical and radiological characteristics of lung disease in inflammatory bowel disease.  Eur Respir J. 2000;  15 41-48 (III)
    Google Scholar
  • 41 Tromm A, Höltmann B, Hüppe D. et al . Hyperamylasämie, Hyperlipasämie und akute Pankreatitiden bei chronisch entzündlichen Darmerkrankungen.  Leber Magen Darm. 1991;  1 15-22 (III)
    Google Scholar
  • 42 Niemelä S, Lehtola J, Karttunen T. et al . Pancreatitis in patients with chronic inflamatory bowel disease.  Hepatogastroenterol. 1989;  36 175-177 (III)
    Google Scholar
  • 43 Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn’s disease.  J Clin Gastroenterol. 1993;  17 286-291 (III)
    Google Scholar
  • 44 Rasmussen H H, Fonager K, Sorensen H AT. et al . Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study.  Scand J Gastroenterol. 1999;  34 199-201 (III)
    Google Scholar
  • 45 Spiess S E, Braun M, Vogelzang R L. et al . Crohn’s disease of the duodenum complicated by pancreatitis and common bile duct obstruction.  Am J Gastroenterol. 1992;  87 1033-1036 (IV)
    Google Scholar
  • 46 Herrlinger K R, Stange E F. The pancreas and inflammatory bowel disease.  Int J Pancreatol. 2001;  27 171-179 (IV)
    Google Scholar
  • 47 Heikius B, Niemela S, Lehtola J. et al . Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease.  Am J Gastroenterol. 1999;  94 1062-1069 (IIb)
    Google Scholar
  • 48 Katz S, Bank S, Greenberg R E. et al . Hyperamylasemia in inflammatory bowel disease.  J Clin Gastroenterol. 1988;  10 627-630 (III)
    Google Scholar
  • 49 Heikius B, Niemelä S, Lehtola J. et al . Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease.  Scand J Gastroenterol. 1996;  31 517-523 (IIb)
    Google Scholar
  • 50 Heikius B, Niemelä S, Lehtola J. et al . Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1997;  32 153-161 (IIb)
    Google Scholar
  • 51 Seibold F, Mork H, Tanza S. et al . Pancreatic autoantibodies in Crohn’s disease: a family study.  GUT. 1997;  40 481-484 (IIb)
    Google Scholar
  • 52 Herrlinger K R, Noftz M K, Fellermann K, Schmidt K, Steinhoff J, Stange E F. Minimal renal dysfunction in inflammtory bowel disease is related to disease activity but not to 5-ASA use.  Aliment Pharm Therap. 2001;  15 363-369 (IIb)
    Google Scholar
  • 53 Kreisel W, Wolf L M, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.  Eur J Gastroenterol Hepatol. 1996;  8 461-468 (III)
    Google Scholar
  • 54 Lossos A Y, River A, Steiner E. et al . Neurologic aspects of inflammatory bowel disease.  Neurology. 1995;  45 416-421 (III)
    Google Scholar
  • 55 Brohee P, Violon P, Mavroudakis N. et al . Central nervous system lesions associated with Crohn’s disease.  J Neuroimaging. 1997;  7 195-198
    Google Scholar
  • 56 Geissler A, Andus T, Roth M. et al . Focal white-matter lesions in brain of patients with inflammatory bowel disease.  Lancet. 1995;  345 897-898 (III)
    Google Scholar
  • 57 Wakefield A J, Sawyerr A M, Dhillon A P. et al . Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction.  Lancet. 1989;  2 1057-1062
    Google Scholar
  • 58 Wakefield A J, Sankey E A, Dhillon A P. et al . Granulomatous vasculitis in Crohn’s disease.  Gastroenterology. 1991;  100 1279-1287
    Google Scholar
  • 59 Talbot R W, Heppell J, Dozois R R. et al . Vascular complications of inflammatory bowel disease.  Mayo Clin Proc. 1986;  61 140-145 (III)
    Google Scholar
  • 60 Bernstein C N, Blanchard J F, Houston D S. et al . The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.  Thromb Haemost. 2001;  83 430-434 (IIb)
    Google Scholar
  • 61 Koutroubakis I E. Role of thrombotic vascular risk factors in inflammatory bowel disease.  Digest Dis. 2000;  18 161-167 (IIb)
    Google Scholar
  • 62 Jackson L M, O’Gorman P J, O’Connell J. et al . Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.  QJM. 1997;  90 183-188 (IIb)
    Google Scholar
  • 63 Lapidus A, Bangstad M, Astrom M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn’s disease.  Am J Gastroenterol. 1999;  94 1261-1266 (Ib)
    Google Scholar
  • 64 Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn’s disease.  Inflammatory Bowel Diseases. 1998;  4 89-94 (IIa)
    Google Scholar
  • 65 Brink M A. et al . Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn’s disease.  Gastroenterology. 1999;  116 1420-1427 (IIa)
    Google Scholar
  • 66 Hylander E, Jarnum S, Jensen H J, Thale M. Enteric hyperoxaluria:dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease.  Scand J Gastroenterol. 1978;  13 577-588 (IIb)
    Google Scholar
  • 67 Stelzner M, Philips J D, Saleh S, Fonkalsrud E W. Nephrolithiasis and urine ion changes in ulcerative colitis undergoing colectomy and endorectal ileal pullthrough.  J Surg Res. 1990;  48 552-556 (III)
    Google Scholar
  • 68 Chadwick V S, Modha K, Dowling R H. Mechanism for hyperoxaluria in patients with ileal dysfunction.  N Engl J Med. 1973;  289 172 (III)
    Google Scholar
  • 69 Bohles H, Beifuss O J, Brandl U, Pichl J, Akcetin Z, Demling L. Urinary factors of kidney stone formation in patients with Crohn's disease.  Klin Wochenschr. 1988;  66 87-91 (III)
    Google Scholar
  • 70 Manganiotis A N, Banner M P, Malkowicz S B. Urologic complications of Crohn's disease.  Surg Clin North Am. 2001;  81 197-215 (III)
    Google Scholar
  • 71 Sato S, Sasaki I, Naito H. et al . Management of urinary complications in Crohn's disease.  Surg Today. 1999;  29 713-717 (III)
    Google Scholar
  • 72 McLeod R S, Churchill D N. Urolithiasis complicating inflammatory bowel disease.  J Uro. 1992;  148 979 (III)
    Google Scholar
  • 73 Kleinhans G, Leusmann D, Pohl J, Pott G. Urologische Komplikationen bei 200 Patienten mit Morbus Crohn.  Z Gastroenterol. 1985;  23 362-374 (III)
    Google Scholar
  • 74 Fukushima T, Sugita A, Masuzawa S, Yamazaki Y, Takemura H, Tsuchiya S. Prevention of uric acid stone formation by sodium bicarbonate in an ileostomy patient - a case report.  Jpn J Surg. 1988;  18 165-168 (III)
    Google Scholar
  • 75 D’Cruz D P, Gertner D J, Kasidas G P, Rampton D S, Rose G A, Samuell C T. Failure of allopurinol to modify urinary composition in enteric hyperoxaluria.  Br J Urol. 1989;  64 231-234 (IIb)
    Google Scholar
  • 76 Bernstein C N, Seeger L L, Sayre J W. et al . Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.  J Bone Miner Res. 1995;  10 250-256 (III)
    Google Scholar
  • 77 Ardizzone S, Bollani S, Bettica P. et al . Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis.  J Intern Med. 2000;  247 63-70 (III)
    Google Scholar
  • 78 Silvennoinen J A, Karttunen T J, Niemela S E. et al . A controlled study of bone mineral density in patients with inflammatory bowel disease.  Gut. 1995;  37 71-76 (III)
    Google Scholar
  • 79 von Tirpitz C, Pischulti G, Rieber A. et al . Pathologische Knochendichte bei chronisch entzündlichen Darmerkrankungen - Prävalenz und Risikofaktoren.  Z Gastroenterologie. 1999;  37 5-12 (III)
    Google Scholar
  • 80 Clements D, Motley R J, Evans W D. et al . Longitudinal study of cortical bone loss in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1992;  27 1055-1060 (III)
    Google Scholar
  • 81 Andreassen H, Rungby J, Dahlerup J F. Inflammatory bowel disease and osteoporosis.  Scand J Gastroenterol. 1997;  32 1247-1255 (III)
    Google Scholar
  • 82 Silvennoinen J A, Lehtola J K, Niemela S E. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease.  Scand J Gastroenterol. 1996;  31 367-371 (IIb)
    Google Scholar
  • 83 von Tirpitz C, Kohn C, Steinkamp M. et al . Lactose intolerance in active Crohn’s disease.  J Clin Gastroenterol. 2002;  34 49-53 (IIb)
    Google Scholar
  • 84 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.  BMJ. 1996;  312 1254-1259 (Ia)
    Google Scholar
  • 85 Klaus J, Armbrecht G, Steinkamp M. et al . High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease.  Gut. 2002;  51 654-688 (IIb)
    Google Scholar
  • 86 Vestergaard P, Krogh K, Rejnmark L. et al . Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis.  Gut. 2000;  46 176-181 (IIb)
    Google Scholar
  • 87 Bernstein C N, Blanchard J F, Leslie W. et al . The Incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.  Ann Intern Med. 2000;  133 795-799 (IIb)
    Google Scholar
  • 88 Vogelsang H, Ferenci P, Resch H. et al . Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation.  Eur J Gastroenterol Hepatol. 1995;  7 609-614 (Ib)
    Google Scholar
  • 89 von Tirpitz C, Klaus K, Brückel J. et al . Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease.  Eur J Gastroenterol Hepatol. 2000;  11 19-24 (Ib)
    Google Scholar
  • 90 Adachi J D, Bensen W G, Bianchi F. et al . Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up.  J Rheumatol. 1996;  23 995-1000 (Ib)
    Google Scholar
  • 91 Buckley L M, Leib E S, Cartularo K S. et al . Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1996;  125 961-968 (Ib)
    Google Scholar
  • 92 Clements D, Compston J E, Evans W D. et al . Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.  Gut. 1993;  34 1543-1546 (Ib)
    Google Scholar
  • 93 Haderslev K V, Tjellesen L, Sorensen H A. et al . Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease.  Gastroenterology. 2000;  119 639-646 (Ib)
    Google Scholar
  • 94 Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.  Br J Rheumatol. 1994;  33 348-350 (Ib)
    Google Scholar
  • 95 Roux C, Oriente P, Laan R. et al . Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.  J Clin Endocrinol Metab. 1998;  83 1128-1133 (Ib)
    Google Scholar
  • 96 Adachi J D, Bensen W G, Brown J. et al . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.  N Engl J Med. 1997;  337 382-387 (Ib)
    Google Scholar
  • 97 Lems W F, Jacobs W G, Bijlsma J W. et al . Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.  Osteoporos Int. 1997;  7 575-582 (Ib)
    Google Scholar
  • 98 Pak C Y, Sakhaee K, Adams H uet B. et al . Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.  Ann Intern Med. 1995;  123 401-408 (Ib)
    Google Scholar
  • 99 Riggs B L, Hodgson S F, O’Fallon W M. et al . Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.  N Engl J Med. 1990;  322 802-809 (Ib)
    Google Scholar
  • 100 Greenstein A J, Sachar D B, Panday A K. et al . Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients.  Medicine. 1992;  71 261-270 (III)
    Google Scholar
  • 101 Wester A L, Vatn M H, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998.  Inflamm Bowel Dis. 2001;  7 295-300 (III)
    Google Scholar